These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33526378)

  • 1. Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.
    Kim HK; Lee HS; Heo MH; Kim JY; Ahn JS; Im YH; Lee JI; Park YH
    Clin Breast Cancer; 2021 Aug; 21(4):e402-e414. PubMed ID: 33526378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis.
    Omuro AM; Lallana EC; Bilsky MH; DeAngelis LM
    Neurology; 2005 May; 64(9):1625-7. PubMed ID: 15883329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.
    Lee S; Ahn HK; Park YH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Park KT; Ahn JS; Im YH
    Breast Cancer Res Treat; 2011 Oct; 129(3):809-17. PubMed ID: 21785952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
    Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
    Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
    Huppert LA; Fisch S; Tsopurashvili E; Somepalle SS; Salans M; Vasudevan HN; Jo Chien A; Majure M; Rugo HS; Balassanian R; Boreta L; Melisko ME
    Breast Cancer Res Treat; 2024 Aug; 206(3):625-636. PubMed ID: 38888796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
    Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
    Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptomeningeal disease and breast cancer: the importance of tumor subtype.
    Abouharb S; Ensor J; Loghin ME; Katz R; Moulder SL; Esteva FJ; Smith B; Valero V; Hortobagyi GN; Melhem-Bertrandt A
    Breast Cancer Res Treat; 2014 Aug; 146(3):477-86. PubMed ID: 25038877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of capecitabine for central nervous system metastases from breast cancer.
    Gouveia MC; Hidalgo Filho CM; Moreno RA; Alves HCBR; Ayres AS; Testa L; Bonadio RC
    Ecancermedicalscience; 2023; 17():1638. PubMed ID: 38414937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis.
    Lee SH; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2011 Sep; 104(2):545-51. PubMed ID: 21274592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumboperitoneal shunt for the treatment of leptomeningeal metastasis.
    Zhang XH; Wang XG; Piao YZ; Wang P; Li P; Li WL
    Med Hypotheses; 2015 May; 84(5):506-8. PubMed ID: 25754849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials.
    Criscitiello C; Marra A; Morganti S; Zagami P; Gandini S; Esposito A; Curigliano G
    Eur J Cancer; 2021 Nov; 157():40-49. PubMed ID: 34474219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic breast cancer subtypes and central nervous system metastases.
    Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
    Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype.
    Zanardi E; Di Meglio A; Boccardo C; Zinoli L; Salvi S; Rubagotti A
    Oncol Res Treat; 2020; 43(7-8):362-371. PubMed ID: 32512573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.